Clinical Trial Update: A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Org 34517 as adjunctive therapy in psychotic major depression; the study has completed evaluating two doses for efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder with Psychotic Features

Drugs mentioned

• ORG 34517

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Depression, Depressive Disorders | Phase 2 | Status: COMPLETED